PF-06651600 for the Treatment of Alopecia Areata
- Conditions
- Alopecia Areata
- Interventions
- Drug: PF-06651600 Induction DoseDrug: PF-06651600 Maintenance Dose #1Drug: PF-06651600 Maintenance Dose #2Drug: PF-06651600 Maintenance Dose #3Drug: Placebo
- Registration Number
- NCT03732807
- Lead Sponsor
- Pfizer
- Brief Summary
This is a global Phase 2b/3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that some patients entering the study will not receive active study drug but will receive tablets with no active ingredients (a placebo). This is a dose-ranging study, investigating 5 different dosing regimens. It will be double-blinded, meaning that the sponsor, the study doctors, the staff, and the patients will not know whether a patient is on active study drug (or the dose) or placebo.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 718
- Clinical diagnosis of alopecia areata with no other cause of hair loss
- ≥50% hair loss of the scalp, including alopecia totalis and alopecia universalis, without evidence of terminal hair regrowth within 6 months
- Current episode of hair loss ≤10 years
- Other types of alopecia or other diseases that can cause hair loss
- Other scalp diseases that could interfere with assessment of hair loss/regrowth
- Subjects with shaved heads must not enter the study until hair has grown back & is considered stable by the investigator
- Any previous use of any Janus kinase (JAK) inhibitor
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Sequence B PF-06651600 Induction Dose Induction dose given QD for 4 weeks followed by maintenance dose #2 given QD for 44 weeks Sequence G PF-06651600 Maintenance Dose #1 Placebo given QD for 24 weeks followed by maintenance dose #1 given QD for 24 weeks Sequence G Placebo Placebo given QD for 24 weeks followed by maintenance dose #1 given QD for 24 weeks Sequence D PF-06651600 Maintenance Dose #2 Maintenance dose #2 given QD for 48 weeks Sequence E PF-06651600 Maintenance Dose #3 Maintenance dose #3 given QD for 48 weeks Sequence B PF-06651600 Maintenance Dose #2 Induction dose given QD for 4 weeks followed by maintenance dose #2 given QD for 44 weeks Sequence C PF-06651600 Maintenance Dose #1 Maintenance dose #1 given QD for 48 weeks Sequence F PF-06651600 Maintenance Dose #1 Placebo given QD for 24 weeks followed by induction dose given QD for 4 weeks then maintenance dose #1 given QD for 20 weeks Sequence A PF-06651600 Maintenance Dose #1 Induction dose given once daily (QD) for 4 weeks followed by maintenance dose #1 given QD for 44 weeks Sequence F Placebo Placebo given QD for 24 weeks followed by induction dose given QD for 4 weeks then maintenance dose #1 given QD for 20 weeks Sequence A PF-06651600 Induction Dose Induction dose given once daily (QD) for 4 weeks followed by maintenance dose #1 given QD for 44 weeks Sequence F PF-06651600 Induction Dose Placebo given QD for 24 weeks followed by induction dose given QD for 4 weeks then maintenance dose #1 given QD for 20 weeks
- Primary Outcome Measures
Name Time Method Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24 Week 24 SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. In this outcome measure, percentage of participants with SALT score less than or equal to (\<=) 20 at week 24 were reported.
- Secondary Outcome Measures
Name Time Method Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 4 Week 24 SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. In this outcome measure, percentage of participants with SALT score \<= 10 at week 24 were reported.
Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 1 Week 24 SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. In this outcome measure, percentage of participants with SALT score \<= 10 at week 24 were reported.
Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 20 at Week 24: Maximum Effect (Emax) Model Week 24 The exposure response of Ritlecitinib (PF-06651600) on the regrowth of scalp hair was characterized using a Bayesian three-parameter hyperbolic Emax model for the SALT score \<=20 at Week 24 with an additional term for effect of loading dose. In Emax exposure-response model the response function was the log odds of the percentage of participants with response based on SALT \<=20 at Week 24, which was fit on the logistic scale and then back-transformed to percentage. The effect of loading dose is included as fixed factor in the model. The variable that represents loading dose has values of 1 for groups 200/50 mg once daily and 200/30 mg once daily and of 0 for the remaining groups. SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease.
Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48 Week 4, 8, 12, 18, 24, 28, 34, 40, and 48 EBA is a numeric rating scale developed to characterize eyebrow hair loss. The numeric rating scale ranges from 0 (none) to 3 (normal), where, 0= no eyebrow, 1=minimal eyebrow, 2=moderate eyebrow and 3= normal eyebrow, where higher scores represent less hair loss of eyebrows.
Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48 Week 4, 8, 12, 18, 24, 28, 34, 40, and 48 ELA is a numeric rating scale developed to characterize eyelash hair loss. The numeric rating scale ranges from 0 (none) to 3 (normal), where, 0=no eyelash, 1=minimal eyelash, 2=moderate eyelash and 3=normal eyelash, where higher scores represent less hair loss of eyelash.
Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations Baseline (Day 1), Week 4, 8, 12, 18, and 24 AAPPO scale is 11-item self-administered questionnaire that measured hair loss, emotional symptoms, and activity limitations over past week. Items 1-4 assessed current hair loss, eyebrow loss, eyelash loss and body hair loss and were analyzed separately on scale of 0-4, with 0 ='no hair loss' and 4='complete hair loss'. Items 5-8 assessed emotional symptoms. Response choices on these items were scored from 0 ='never' to 4='always'. Items 9-11 assessed activity limitations. Response choices on these items were scored from 0='not at all' to 4='completely'. Change from baseline in AAPPO emotional symptoms sub score were calculated as mean of items 5-8 and ranged from 0(never) to 4(always), where higher scores indicated more emotional symptoms. Change from baseline in AAPPO activity limitations sub score was calculated as mean of items 9-11 and ranged from 0(not at all) to 4(completely), where higher scores indicated more activity limitations. Baseline was defined as pre-dose on Day 1.
Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 24 Week 24 PGI-C is a self-administered questionnaire to evaluate the improvement or worsening of participant's AA as compared to the start of the study. PGI-C was assessed on a 7-point Likert scale ranged from 1 (greatly improved) to 7 (greatly worsened). Categories were defined based on the PGI-C scores as follows: 1=greatly improved, 2=moderately improved, 3=slightly improved, 4=not changed, 5=slightly worsened, 6=moderately worsened and 7=greatly worsened.
Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 10 at Week 24: Maximum Effect (Emax) Model Week 24 The exposure response of Ritlecitinib (PF-06651600) on the regrowth of scalp hair was characterized using a Bayesian three-parameter hyperbolic Emax model for the SALT score \<=10 at Week 24 with an additional term for effect of loading dose. In Emax exposure-response model the response function was the log odds of the percentage of participants with response based on SALT \<=10 at Week 24, which was fit on the logistic scale and then back-transformed to percentage. The effect of loading dose is included as fixed factor in the model. The variable that represents loading dose has values of 1 for groups 200/50 mg once daily and 200/30 mg once daily and of 0 for the remaining groups. SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease.
Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48 Week 4, 8, 12, 18, 28, 34, 40, and 48 SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. In this outcome measure, percentage of participants with SALT score \<=10 were reported.
Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48 Week 4, 8, 12, 18, 24, 28, 34, 40, and 48 SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. A SALT 75 response was a 75% or greater reduction from baseline in SALT score.
Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24 Baseline (Day 1), Week 4, 8, 12, 18, and 24 SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. Baseline was defined as pre-dose on Day 1.
Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48 Week 4, 8, 12, 18, 24, 34, 40, and 48 PGI-C is a self-administered questionnaire to evaluate the improvement or worsening of participant's AA as compared to the start of the study. PGI-C was assessed on a 7-point Likert scale ranged from 1 (greatly improved) to 7 (greatly worsened). Categories were defined based on the PGI-C scores as follows: 1=greatly improved, 2=moderately improved, 3=slightly improved, 4=not changed, 5=slightly worsened, 6=moderately worsened and 7=greatly worsened.
Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48 Week 4, 8, 12, 18, 28, 34, 40, and 48 SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease.
Change From Baseline in SALT Score at Week 28, 34, 40, and 48 Baseline (Day 1), Week 28, 34, 40, and 48 SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. Baseline was defined as pre-dose on Day 1.
Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations Baseline (Day 1), Week 34, 40, and 48 AAPPO scale is 11-item self-administered questionnaire that measured hair loss, emotional symptoms, and activity limitations over past week. Items 1-4 assessed current hair loss, eyebrow loss, eyelash loss and body hair loss and were analyzed separately on scale of 0-4, with 0 ='no hair loss' and 4='complete hair loss'. Items 5-8 assessed emotional symptoms. Response choices on these items were scored from 0 ='never' to 4='always'. Items 9-11 assessed activity limitations. Response choices on these items were scored from 0='not at all' to 4='completely'. Change from baseline in AAPPO emotional symptoms sub score were calculated as mean of items 5-8 and ranged from 0(never) to 4(always), where higher scores indicated more emotional symptoms. Change from baseline in AAPPO activity limitations sub score was calculated as mean of items 9-11 and ranged from 0(not at all) to 4(completely), where higher scores indicated more activity limitations. Baseline was defined as pre-dose on Day 1.
Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48 Week 4, 8, 12, 18, 24, 34, 40, and 48 AAPPO scale is a 11-item self-administered questionnaire that measured hair loss, emotional symptoms, and activity limitations over the past week. Items 1-4 were to assess the current hair loss, eyebrow loss, eyelash loss and body hair loss and were analyzed separately on a scale of 0-4, with 0 ='no hair loss' and 4='complete hair loss', where higher scores indicated more hair loss.
Trial Locations
- Locations (153)
Mosaic Dermatology
🇺🇸Beverly Hills, California, United States
Dermatology Specialists, Inc.
🇺🇸Murrieta, California, United States
University of California, Irvine, Department of Dermatology, Dermatology Clinical Research Center
🇺🇸Irvine, California, United States
Southern California Dermatology, Inc.
🇺🇸Santa Ana, California, United States
Medstar Georgetown University Hospital Center-Department of Pediatrics
🇺🇸Washington, District of Columbia, United States
Medstar Washington Hospital Center
🇺🇸Washington, District of Columbia, United States
Medstar Washington Hospital Center-Claude Nogay Research Pharmacy
🇺🇸Washington, District of Columbia, United States
Siperstein Dermatology Group
🇺🇸Boynton Beach, Florida, United States
Park Avenue Dermatology
🇺🇸Orange Park, Florida, United States
Advanced Clinical Research
🇺🇸Meridian, Idaho, United States
NorthShore University HealthSystem
🇺🇸Skokie, Illinois, United States
Southern Illinois University School of Medicine
🇺🇸Springfield, Illinois, United States
University of Iowa Hospitals and Clinics; Department of Pharmacy-IDS;
🇺🇸Iowa City, Iowa, United States
University of Iowa Hospitals and Clinics
🇺🇸Iowa City, Iowa, United States
Medstar Georgetown University Hospital - Department of Dermatology
🇺🇸Chevy Chase, Maryland, United States
NYU School of Medicine, The Ronald O. Perelman Department of Dermatology
🇺🇸New York, New York, United States
Icahn School of Medicine at Mount Sinai
🇺🇸New York, New York, United States
Vital Prospects Clinical Research Institute, P.C
🇺🇸Tulsa, Oklahoma, United States
Psoriahue Medicina Interdisciplinaria
🇦🇷Caba, Argentina
Premier Specialists Pty Ltd
🇦🇺Kogarah, New South Wales, Australia
St George Dermatology and Skin Cancer Centre
🇦🇺Kogarah, New South Wales, Australia
The Skin Centre
🇦🇺Benowa, Queensland, Australia
Veracity Clinical Research Pty Ltd
🇦🇺Woolloongabba, Queensland, Australia
Sinclair Dermatology
🇦🇺East Melbourne, Victoria, Australia
Guenther Research Inc
🇨🇦London, Ontario, Canada
The Centre for Clinical Trials
🇨🇦Oakville, Ontario, Canada
York Dermatology Clinic and Research Centre
🇨🇦Richmond Hill, Ontario, Canada
SKiN Centre for Dermatology
🇨🇦Peterborough, Ontario, Canada
Medicor Research Inc
🇨🇦Sudbury, Ontario, Canada
Centre de Recherche Dermatologique du Quebec metropolitain
🇨🇦Quebec, Canada
Sudbury Skin Clinique
🇨🇦Sudbury, Ontario, Canada
Innovaderm Research Inc.
🇨🇦Montreal, Quebec, Canada
Centro Internacional de Estudios Clinicos, CIEC
🇨🇱Santiago, Recoleta, Chile
Centro Medico Skin Med
🇨🇱Santiago, Región Metropolitana, Chile
Clinica Dermacross S.A.
🇨🇱Santiago, Región Metropolitana, Chile
Peking University First Hospital
🇨🇳Beijing, Beijing, China
Medical Skin Center
🇨🇱Vina del Mar, Valparaiso, Chile
Beijing Friendship Hospital, Capital Medical University
🇨🇳Beijing, Beijing, China
Peking University Third Hospital
🇨🇳Beijing, Beijing, China
The First Affiliated Hospital, Sun Yat-sen University
🇨🇳Guangzhou, Guangdong, China
The University of Hong Kong - Shenzhen Hospital
🇨🇳Shenzhen, Guangdong, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
🇨🇳Wuhan, Hubei, China
The First Affiliated Hospital with Nanjing Medical University
🇨🇳Nanjing, Jiangsu, China
The First Affiliated Hospital of College of Medicine, Zhejiang University
🇨🇳Hangzhou, Zhejiang, China
Huashan Hospital, Fudan University/Dermatology Department
🇨🇳Shanghai, Shanghai, China
The Second Affiliated Hospital of College of Medicine, Zhejiang University/Dermatology Dept
🇨🇳Hangzhou, Zhejiang, China
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
🇨🇳Shanghai, China
Fundacion Centro de Investigacion Clinica CIC
🇨🇴Medellin, Antioquia, Colombia
DERMAMEDICA s.r.o.
🇨🇿Nachod, Czechia
Fakultni nemocnice Olomouc
🇨🇿Olomouc, Czechia
Emovis GmbH
🇩🇪Berlin, Germany
Nemocnice Na Bulovce
🇨🇿Praha 8- Liben, Czechia
Clintrial s.r.o.
🇨🇿Praha 10, Czechia
Sanatorium profesora Arenbergera
🇨🇿Praha 1, Czechia
University Hospital Frankfurt
🇩🇪Frankfurt am Main, Germany
Fachklinik Bad Bentheim
🇩🇪Bad Bentheim, Germany
Universitaetsklinikum Erlangen
🇩🇪Erlangen, Germany
University Hospital Schleswig-Holstein
🇩🇪Luebeck, Germany
University Hospital Muenster
🇩🇪Muenster, Germany
Szegedi Tudományegyetem Altalanos Orvostudomanyi Kar
🇭🇺Szeged, Hungary
Nagoya City University Hospital - Dermatology
🇯🇵Nagoya, Aichi, Japan
Osaka City University Hospital
🇯🇵Osaka, Japan
Pusan National University Hospital
🇰🇷Busan, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Hospital D'Maria
🇲🇽Veracruz, Mexico
Centermed Krakow Sp.z o.o.
🇵🇱Krakow, Poland
Dermoklinika Centrum Medyczne s.c., M. Kierstan, J. Narbutt, A. Lesiak
🇵🇱Lodz, Poland
Royalderm Agnieszka Nawrocka
🇵🇱Warszawa, Poland
Cityclinic Przychodnia Lekarsko Psychologiczna Matusiak Spółka Partnerska
🇵🇱Wroclaw, Poland
Clinical Medical Center of A.I. Yevdokimov MSMSU
🇷🇺Moscow, Russian Federation
Limited Liability Company "Pierre Volkenshtein Skin Diseases Clinic"
🇷🇺Saint Petersburg,, Russian Federation
Limited Liability Company "Centre Vitiligo" ("Centre Vitiligo" LLC)
🇷🇺Saint Petersburg, Russian Federation
Saint Petersburg State Budgetary Healthcare Institution "Dermatovenerologic Dispensary No. 10 -
🇷🇺Saint Petersburg, Russian Federation
Hospital del Mar
🇪🇸Barcelona, Spain
Hospital Universitari Germans Trias i Pujol
🇪🇸Badalona, Barcelona, Spain
Hospital Universitario Reina Sofía, Servicio Dermatologia
🇪🇸Cordoba, Spain
Servicio Otorrinolaringologia, Hospital Universitario Reina Sofia
🇪🇸Cordoba, Spain
Servicio Radiologia, Hospital Universitario Reina Sofia
🇪🇸Cordoba, Spain
Hospital Universitario Infanta Leonor
🇪🇸Madrid, Spain
Hospital Universitario La Paz
🇪🇸Madrid, Spain
Servicio de Dermatologia, Hospital Universitario y Politecnico La Fe
🇪🇸Valencia, Spain
CHANG GUNG MEMORIAL HOSPITAL Kaohsiung Branch
🇨🇳Kaohsiung City, Taiwan
Servicio de Otorrinolaringologia, Hospital Universitario y Politecnico La Fe
🇪🇸Valencia, Spain
Servicio de Radiologia, Hospital Universitario y Politecnico Le Fe
🇪🇸Valencia, Spain
Kaohsiung Medical University Chung-Ho Memorial Hospital
🇨🇳Kaohsiung, Taiwan
Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare
🇨🇳New Taipei City, Taiwan
Chang Gung Memorial Hospital-Linkou Branch
🇨🇳Taoyuan City, Taiwan
Brighton and Sussex University Hospitals NHS Trust
🇬🇧Brighton, United Kingdom
Southampton University Hospital NHS Foundation Trust, Royal South Hants Hospital
🇬🇧Southampton, Hampshire, United Kingdom
NHS Greater Glasgow and Clyde Queen Elizabeth University Hospital
🇬🇧Glasgow, United Kingdom
NHS Greater Glasgow and Clyde
🇬🇧Glasgow, United Kingdom
NHS Tayside Ninewells Hospital
🇬🇧Dundee, United Kingdom
Southampton University Hospital NHS Foundation Trust, University Hospital Southampton
🇬🇧Hampshire, United Kingdom
Guy's and St.Thomas' Hospitals NHS Foundation Trust, St.Thomas' Hospital,
🇬🇧London,, United Kingdom
Guy's and St.Thomas' Hospitals NHS Foundation Trust, Guy's Hospital,
🇬🇧London,, United Kingdom
Northwestern University
🇺🇸Chicago, Illinois, United States
Dawes Fretzin Clinical Research Group, LLC
🇺🇸Indianapolis, Indiana, United States
University of Minnesota Medical Center, Investigational Drug Services Attn: Darlette Luke
🇺🇸Minneapolis, Minnesota, United States
Northwestern Medical Group
🇺🇸Chicago, Illinois, United States
Lynderm Research Inc.
🇨🇦Markham, Ontario, Canada
Northwestern Medicine
🇺🇸Chicago, Illinois, United States
University of Minnesota Department of Dermatology
🇺🇸Minneapolis, Minnesota, United States
Cleveland Clinic Foundation
🇺🇸Cleveland, Ohio, United States
Northwestern Medicine Diagnostic Testing Center
🇺🇸Chicago, Illinois, United States
Northwestern Memorial Hospital, Investigational Research Pharmacy
🇺🇸Chicago, Illinois, United States
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States
The University of Texas Health Science Center at Houston
🇺🇸Houston, Texas, United States
Research Toronto
🇨🇦Toronto, Ontario, Canada
Wiseman Dermatology Research Inc.
🇨🇦Winnipeg, Manitoba, Canada
University of California, San Francisco
🇺🇸San Francisco, California, United States
Kaiser Permanente Clinical Trials Unit
🇺🇸San Francisco, California, United States
The University of Alabama at Birmingham Hospital Outreach Lab
🇺🇸Birmingham, Alabama, United States
The University of Alabama at Birmingham, Department of Dermatology
🇺🇸Birmingham, Alabama, United States
Eastern Canada Cutaneous Research Associates Ltd.
🇨🇦Halifax, Nova Scotia, Canada
CINME Centro de Investigaciones Metabolicas
🇦🇷Caba, Buenos Aires, Argentina
Fundacion Hospitalaria San Vicente de Paul
🇨🇴Medellin, Antioquia, Colombia
Debreceni Egyetem
🇭🇺Debrecen, Hungary
Juntendo Tokyo Koto Geriatric Medical Center
🇯🇵Koto-ku, Tokyo, Japan
Medicover Sp.z.o.o
🇵🇱Lodz, Poland
Medstar Georgetown University Hospital Center-Department of Otolaryngology
🇺🇸Washington, District of Columbia, United States
The Royal Melbourne Hospital
🇦🇺Parkville, Victoria, Australia
Sanova Audiological Care Polska Sp.z.o.o
🇵🇱Lodz, Poland
Royal Park Campus
🇦🇺Parkville, Victoria, Australia
The Dermatology Group, P.C.
🇺🇸Verona, New Jersey, United States
Skin Health Institute
🇦🇺Carlton, Victoria, Australia
Centro de Investigación en Reumatología y Especialidades Médicas SAS - CIREEM SAS
🇨🇴Bogota, D.c., Colombia
Bugat Pal Korhaz, Borgyogyaszat
🇭🇺Gyongyos, Hungary
Hamamatsu University Hospital
🇯🇵Hamamatsu, Shizuoka, Japan
University Clinic of Kirov SMU
🇷🇺Kirov, Russian Federation
State Autonomous Healthcare Institution of the Yaroslavl Region Clinical Emergency Hospital
🇷🇺Yaroslavl, Russian Federation
Chung-Shan Medical University Hospital
🇨🇳Taichung, Taiwan
Semmelweis Egyetem
🇭🇺Budapest, Hungary
Tohoku University hospital
🇯🇵Sendai, Miyagi, Japan
Tokyo Medical University Hospital
🇯🇵Shinjuku-ku, Tokyo, Japan
Sociedad de Metabolismo y Corazon S.C.
🇲🇽Veracruz, Mexico
Chung Shan Medical University Hospital
🇨🇳Taichung, Taiwan
Twoja Przychodnia - Szczecinskie Centrum Medyczne
🇵🇱Szczecin, Poland
RCMed Oddzial Warszawa
🇵🇱Warszawa, Poland
State Budgetary Healthcare Institution Chelyabinsk Regional Clinical Dermatovenerologic Dispensary
🇷🇺Chelyabinsk, Russian Federation
Federal State Autonomous Institution National Medical Research Centre of Childrens Health
🇷🇺Moscow, Russian Federation
State Budgetary Institution of the Rostov Region "Dermatovenerologic Dispensary"
🇷🇺Rostov-on-Don, Russian Federation
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
Harley Grove Medical Centre
🇬🇧London, United Kingdom
University of Colorado Anschutz Medical Campus
🇺🇸Aurora, Colorado, United States
University of Colorado Hospital Clinical and Translational Research Center
🇺🇸Aurora, Colorado, United States
Skin Specialists, PC
🇺🇸Omaha, Nebraska, United States
Church Street Research Unit
🇺🇸New Haven, Connecticut, United States
Yale School of Medicine
🇺🇸New Haven, Connecticut, United States
University of Colorado Hospital Outpatient Pavillion
🇺🇸Aurora, Colorado, United States
UNC CTRC
🇺🇸Chapel Hill, North Carolina, United States
UNC Hospitals, Investigational Drug Service
🇺🇸Chapel Hill, North Carolina, United States
UNC Dermatology Clinical Trials Unit
🇺🇸Chapel Hill, North Carolina, United States
ForCare Clinical Research
🇺🇸Tampa, Florida, United States